January 2013 Newsletter

January 24, 2013:

Laser Refractive Cataract Surgery Market Shows Early Promise, but IOL Revenues Flatten

The lingering recession produced mixed results in the cataract market.

January 24, 2013:

Predictions for Future LRCS Improvements

We anticipate a number of improvements will be made to LRCS lasers that will increase their value.

January 24, 2013:

2012 Saw Robust Growth in Retinal Surgery Market & Key Device Expanded Glaucoma Treatment Options

Both the retinal surgery and glaucoma surgery markets felt the impact of newer technologies.

January 24, 2013:

2012 Sees Eylea Gain Share, CATT Results Upheld, DME Label for Lucentis, & FDA Approval of Jetrea

IVT injections of retinal pharmaceuticals and biologics drove healthy growth in the retinal treatments market.

January 24, 2013:

Refractive Industry Awaits Better Economic Times

Global demand for refractive surgery grew approximately 1 percent during 2012 to just more than 3.8 million procedures, according to Market Scope estimates.

January 24, 2013:

Ophthalmic Ventures Raise $215 Million for New Product Development in 2012

This number is down significantly from 2011, when we tallied more than $350 million.

January 24, 2013:

New Ophthalmic Drugs & Key Added Indications Get FDA Nod in 2012

These included Mobius Therapeutics’ Mitosol and ThromboGenics’ Jetrea.

January 24, 2013:

FDA Approves Key Ophthalmic Devices in 2012

Three new ophthalmic devices successfully completed the US FDA’s regulatory process, and six other products received label expansions during 2012.

January 24, 2013:

Doctors Relieved and Hospitals Riled by Fiscal Cliff Deal That Puts Off Real Medicare Reform

Ophthalmologists who headed into 2013 bracing for a massive cut in Medicare payments received a temporary reprieve in the “fiscal cliff” compromise that Congress signed on New Year’s Day, but hospitals were shouldered with much of the burden to pay for that reprieve.

January 24, 2013:

January 2013 News Briefs

Social media